Join Growin Stock Community!

Kiora pharmaceuticals, inc.KPRX.US Overview

US StockHealthcare
(No presentation for KPRX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

KPRX AI Insights

KPRX Overall Performance

KPRX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

KPRX Recent Performance

-1.44%

Kiora pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

KPRX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

KPRX Key Information

KPRX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

KPRX Profile

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Price of KPRX

KPRX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

KPRX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
363.74
PB Ratio
0.34
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-60257.27%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
363.74
PB Ratio
0.34
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-60257.27%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is KPRX's latest earnings report released?

    The most recent financial report for Kiora pharmaceuticals, inc. (KPRX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating KPRX's short-term business performance and financial health. For the latest updates on KPRX's earnings releases, visit this page regularly.

  • How much debt does KPRX have?

    As of the end of the reporting period, Kiora pharmaceuticals, inc. (KPRX) had total debt of 404.17K, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does KPRX have?

    At the end of the period, Kiora pharmaceuticals, inc. (KPRX) held Total Cash and Cash Equivalents of 5.51M, accounting for 0.18 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is KPRX's EPS continuing to grow?

    According to the past four quarterly reports, Kiora pharmaceuticals, inc. (KPRX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of KPRX?

    Kiora pharmaceuticals, inc. (KPRX)'s Free Cash Flow (FCF) for the period is -1.27M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 238.42% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.